{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:34:07Z","timestamp":1791412447549,"version":"4.3.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T00:00:00Z","timestamp":1522972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T00:00:00Z","timestamp":1522972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00535-018-1455-1","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T15:35:00Z","timestamp":1524152100000},"page":"1142-1150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4000-835X","authenticated-orcid":false,"given":"Keiji","family":"Tsuji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Itakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Takaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitomi","family":"Hasebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Joko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jirou","family":"Takezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryou","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsunori","family":"Kusakabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Kobashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akeri","family":"Mitsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kondou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Sohda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryouichi","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namiki","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,6]]},"reference":[{"key":"1455_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.1840120409","volume":"12","author":"K Kiyosawa","year":"1990","unstructured":"Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12:671\u20135.","journal-title":"Hepatology"},{"key":"1455_CR2","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/hep.510280632","volume":"28","author":"C Niederau","year":"1998","unstructured":"Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998;28:1687\u201395.","journal-title":"Hepatology"},{"key":"1455_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153\u201394.","journal-title":"J Hepatol"},{"key":"1455_CR4","unstructured":"American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org. Accessed 16 Sept 2016."},{"key":"1455_CR5","unstructured":"The Japan Society for Hepatology. JSH guidelines for management of hepatitis C virus infection (ver. 5.2). 2016. http:\/\/www.jsh.or.jp\/medical\/guidelines\/jsh_guidlines\/hepatitis_c. Accessed 15 Dec 2016."},{"key":"1455_CR6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/hep.26442","volume":"58","author":"Y Asahina","year":"2013","unstructured":"Asahina Y, Tsuchiya K, Nishimura T, et al. \u03b1-Fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253\u201362.","journal-title":"Hepatology"},{"key":"1455_CR7","doi-asserted-by":"publisher","first-page":"15584","DOI":"10.1073\/pnas.242608099","volume":"99","author":"Y Tanaka","year":"2002","unstructured":"Tanaka Y, Hanada K, Mizokami M, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA. 2002;99:15584\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1455_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/hep.24724","volume":"55","author":"K Chayama","year":"2012","unstructured":"Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55:724\u20138.","journal-title":"Hepatology"},{"key":"1455_CR9","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083\u201391.","journal-title":"Hepatology"},{"key":"1455_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","volume":"58","author":"Y Suzuki","year":"2013","unstructured":"Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655\u201362.","journal-title":"J Hepatol"},{"key":"1455_CR11","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1586\/14787210.2014.942282","volume":"12","author":"N Izumi","year":"2014","unstructured":"Izumi N. Efficacy of daclatasvir in hepatitis C virus. Exp Rev Anti-Infect Ther. 2014;12:1025\u201331.","journal-title":"Exp Rev Anti-Infect Ther."},{"key":"1455_CR12","doi-asserted-by":"publisher","first-page":"e0165339","DOI":"10.1371\/journal.pone.0165339","volume":"11","author":"J Itakura","year":"2016","unstructured":"Itakura J, Kurosaki M, Hasebe C, et al. Complex pattern of resistance-associated substitutions of hepatitis C virus after daclatasvir\/asunaprevir treatment failure. PLoS One. 2016;11:e0165339.","journal-title":"PLoS One"},{"key":"1455_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","volume":"15","author":"M Mizokami","year":"2015","unstructured":"Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12\u00a0weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomized, phase 3 trial. Lancet Infect Dis. 2015;15:645\u201353.","journal-title":"Lancet Infect Dis."},{"key":"1455_CR14","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00535-016-1290-1","volume":"52","author":"E Ogawa","year":"2017","unstructured":"Ogawa E, Furusyo N, Nomura H, et al. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. J Gastroenterol. 2017;52:845\u201354.","journal-title":"J Gastroenterol"},{"key":"1455_CR15","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3390\/ijms18050906","volume":"18","author":"T Kanda","year":"2017","unstructured":"Kanda T, Yasui S, Nakamura M, et al. Real- world experiences with the combination treatment of ledipasvir plus sofosbuvir for 12\u00a0weeks in HCV genotype 1-infected Japanese patients: achievement of a sustained virological response in previous users of peginterferon plus ribavirin with HCV NS3\/4A inhibitors. Int J Mol Sci. 2017;18:906.","journal-title":"Int J Mol Sci"},{"key":"1455_CR16","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/jvh.12549","volume":"23","author":"M Mizokami","year":"2016","unstructured":"Mizokami M, Dvory-Sobol H, Izumi N, et al. Resistance analyses of Japanese hepatitis C-infected patients receiving sofosbuvir or ledipasvir\/sofosbuvir containing regimens in phase 3 studies. J Viral Hepat. 2016;23:780\u20138.","journal-title":"J Viral Hepat."},{"key":"1455_CR17","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.cgh.2013.11.033","volume":"12","author":"T Oze","year":"2014","unstructured":"Oze T, Hiramatsu N, Yakushijin T, et al. Post-treatment levels of \u03b1-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol. 2014;12:1186\u201395.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1455_CR18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/hepr.12839","volume":"47","author":"T Tada","year":"2017","unstructured":"Tada T, Kumada T, Toyoda H, et al. Post-treatment levels of \u03b1-fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C. Hepatol Res. 2017;47:1021\u201331.","journal-title":"Hepatol Res."},{"key":"1455_CR19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/hepr.12621","volume":"46","author":"E Miyaki","year":"2016","unstructured":"Miyaki E, Hiraga N, Imamura M, et al. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res. 2016;46:758\u201364.","journal-title":"Hepatol Res."},{"key":"1455_CR20","first-page":"43","volume":"5","author":"K Nguyen","year":"2017","unstructured":"Nguyen K, Jimenez M, Moghadam N, et al. Decrease of alpha-fetoprotein in patients with cirrhosis treated with direct-acting antivirals. J Clin Transl Hepatol. 2017;5:43\u20139.","journal-title":"J Clin Transl Hepatol."},{"key":"1455_CR21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","volume":"67","author":"H Nagata","year":"2017","unstructured":"Nagata H, Nakagawa M, Asahina Y, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017;67:933\u20139.","journal-title":"J Hepatol"},{"key":"1455_CR22","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/hep.27305","volume":"60","author":"K Yamasaki","year":"2014","unstructured":"Yamasaki K, Tateyama M, Abiru S, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology. 2014;60:1563\u201370.","journal-title":"Hepatology"},{"key":"1455_CR23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00535-010-0293-6","volume":"46","author":"M Tateyama","year":"2011","unstructured":"Tateyama M, Yatsuhashi H, Taura N, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2011;46:92\u2013100.","journal-title":"J Gastroenterol"},{"key":"1455_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jhep.2008.04.013","volume":"49","author":"H Toyoda","year":"2008","unstructured":"Toyoda H, Kumada T, Kaneoka Y, et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol. 2008;49:223\u201332.","journal-title":"J Hepatol"},{"key":"1455_CR25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jhep.2010.07.033","volume":"54","author":"EA Tsochatzis","year":"2011","unstructured":"Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54:650\u20139.","journal-title":"J Hepatol"},{"key":"1455_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.21669","volume":"46","author":"A Vallet-Pichard","year":"2007","unstructured":"Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32\u20136.","journal-title":"Hepatology"},{"key":"1455_CR27","doi-asserted-by":"publisher","first-page":"e0130022","DOI":"10.1371\/journal.pone.0130022","volume":"10","author":"S Yoshimi","year":"2015","unstructured":"Yoshimi S, Ochi H, Murakami E, et al. Rapid, sensitive, and accurate evaluation of drug resistant mutant (NS5A-Y93H) strain frequency in genotype 1b HCV by invader assay. PLoS One. 2015;10:e0130022.","journal-title":"PLoS One"},{"key":"1455_CR28","doi-asserted-by":"publisher","first-page":"e112647","DOI":"10.1371\/journal.pone.0112647","volume":"9","author":"Y Uchida","year":"2014","unstructured":"Uchida Y, Kouyama J, Naiki K, Mochida S. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9:e112647.","journal-title":"PLoS One"},{"key":"1455_CR29","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/hepr.12316","volume":"44","author":"M Miura","year":"2014","unstructured":"Miura M, Maekawa S, Sato M, et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014;44:360\u20137.","journal-title":"Hepatol Res."},{"key":"1455_CR30","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","volume":"10","author":"M Omata","year":"2016","unstructured":"Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10:702\u201326.","journal-title":"Hepatol Int."},{"key":"1455_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/jmv.24617","volume":"89","author":"N Akuta","year":"2017","unstructured":"Akuta N, Sezaki H, Suzuki F, et al. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. J Med Virol. 2017;89:284\u201390.","journal-title":"J Med Virol"},{"key":"1455_CR32","first-page":"e129053","volume":"10","author":"R Sasaki","year":"2015","unstructured":"Sasaki R, Yamasaki K, Abiru S, et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS One. 2015;10:e129053.","journal-title":"PLoS One"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-018-1455-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-1455-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-1455-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:53:24Z","timestamp":1659056004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-018-1455-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,6]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1455"],"URL":"https:\/\/doi.org\/10.1007\/s00535-018-1455-1","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,6]]},"assertion":[{"value":"14 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}